secwatch.observer — SEC 8-K summary
======================================

Issuer:     vTv Therapeutics Inc. (VTVT)
CIK:        0001641489
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001641489-23-000007
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

vTv Therapeutics reports FY2022 net loss of $19.2M; advances TTP399 toward Phase 3
--------------------------------------------------------------------------------

- Net loss attributable to shareholders was $19.2M ($0.26/share) for FY2022 vs $13.0M ($0.21/share) in FY2021.
- Cash and cash equivalents at Dec 31, 2022: $12.1M, down from $13.4M a year earlier.
- Received ~$12.0M from G42 Investments in Feb 2023 via early promissory note payment at 3.75% discount.
- Appointed Steven Tuch as EVP/CFO (Dec 2022) and Elizabeth Keiley as EVP/General Counsel (Feb 2023).
- Preparing to initiate first of two Phase 3 trials of TTP399 for Type 1 diabetes in H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/0001641489-23-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641489/000164148923000007/vtvt-20230306.htm
  HTML page:      https://secwatch.observer/filing/0001641489-23-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer